Mostrar el registro sencillo del ítem

dc.contributor.authorDios Pérez, Inmaculada de 
dc.contributor.authorGonzález Garcinuño, Álvaro 
dc.contributor.authorMuñoz Barroso, María Isabel 
dc.contributor.authorMartín del Valle, Eva María 
dc.date.accessioned2024-03-21T08:30:01Z
dc.date.available2024-03-21T08:30:01Z
dc.date.issued2024
dc.identifier.issn0022-3549
dc.identifier.urihttp://hdl.handle.net/10366/156838
dc.description.abstract[EN]In order to reduce the side effects of traditional chemotherapy in the treatment of colorectal cancer (CRC), a newdrug delivery system has been developed in this work, based on exosomes that can host two drugs that act synergistically: farnesol (that stops the cell cycle) and paclitaxel (prevents microtubule system depolymerization). Firstly, exosomes were isolated from different cell cultures (from colorectal cancer and from f ibroblast as example of normal cell line) by different methods and characterized by western blot, TEM and DLS, and results showed that they express classical protein markers such as CD9 and HSP-70 and they showed spherical morphology with sizes from 93 nm to 129 nm depending on the source. These exosomes were loaded with both drugs and its effect was studied in vitro. The efficacy was studied by comparing the viability of cell cultures with a colorectal cancer cell line (HCT-116) and a normal cell line (fibroblast HS-5). Results showed that exosomes present a specific effect with more reduction in cell viability in tumour cultures than healthy ones. In summary, exosomes are presented in this work as a promising strategy for colorectal cancer treatmentes_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectColorectal canceres_ES
dc.subjectDrug targetinges_ES
dc.subjectExosomeses_ES
dc.subjectDrug delivery systemses_ES
dc.subjectCell lineses_ES
dc.subjectNanotechnologyes_ES
dc.subjectCyclodextrinses_ES
dc.subjectPoorly water-soluble drugses_ES
dc.subjectFarnesoles_ES
dc.subjectPaclitaxeles_ES
dc.subject.meshExosomes *
dc.subject.meshColorectal Neoplasms *
dc.subject.meshDrug Delivery Systems *
dc.subject.meshCell Line *
dc.subject.meshNanotechnology *
dc.titleA Synergistic Approach Therapy for Colorectal Cancer Based on Exosomes and Exploitation of Metabolic Pathwayses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1016/j.xphs.2023.10.017es_ES
dc.subject.unesco3201.01 Oncologíaes_ES
dc.subject.unesco2412.02 Anticuerposes_ES
dc.identifier.doi10.1016/j.xphs.2023.10.017
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccesses_ES
dc.journal.titleJournal of Pharmaceutical Scienceses_ES
dc.volume.number113es_ES
dc.issue.number4es_ES
dc.page.initial1038es_ES
dc.page.final1046es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsexosomas *
dc.subject.decssistemas de liberación de medicamentos *
dc.subject.decsnanotecnología *
dc.subject.decsneoplasias colorrectales *
dc.subject.decslínea celular *


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional